Amphista Therapeutics
Amphista Therapeutics develops small-molecule therapeutics that selectively degrade disease-causing proteins to treat oncology and neurodegeneration. The company uses a chemistry-first Targeted Glue technology that rationally combines features of PROTACs and molecular glues to expand the range of degradable targets and tissues. Discovery and optimization leverage AI-ML, computational modeling, high-content and multiplexed assays, and native mass spectrometry. Amphista is a biopharmaceutical drug developer with programs targeting BRD9 and SMARCA2 and an emphasis on oral bioavailability and CNS penetration.
Amphista Therapeutics
Amphista Therapeutics develops small-molecule therapeutics that selectively degrade disease-causing proteins to treat oncology and neurodegeneration. The company uses a chemistry-first Targeted Glue technology that rationally combines features of PROTACs and molecular glues to expand the range of degradable targets and tissues. Discovery and optimization leverage AI-ML, computational modeling, high-content and multiplexed assays, and native mass spectrometry. Amphista is a biopharmaceutical drug developer with programs targeting BRD9 and SMARCA2 and an emphasis on oral bioavailability and CNS penetration.